<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, shrink-to-fit=no">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Vericiguat – VICTORIA Çalışması Sonuçları</title>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet">
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/js/bootstrap.bundle.min.js"></script>
  <link rel="stylesheet" href="assets/css/styles.css">
  <link rel="stylesheet" href="assets/fonts/fontawesome-all.min.css">
  <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.7.0/jquery.min.js"></script>
  <script src="assets/js/javascript.js"></script>
</head>

<body>
  <div class="row">
   <h3 style="font-size: 28px; width: 100%; color: white;font-family: helvetica; font-weight: bold; background: #00617f; padding-top: 10px; padding-bottom: 10px;padding-left: 25px;">Vericiguat – VICTORIA Çalışması Sonuçları</h3>
  </div>

  <div class="card">
    <ul class="nav nav-tabs" role="tablist">
      <li class="nav-item" role="presentation"><a class="nav-link active" id="summary_tab" data-bs-toggle="tab" data-bs-target="#summary" href="#summary" role="tab">Özet</a>
      </li>
      <li class="nav-item" role="presentation"><a class="nav-link" id= "methods_tab" data-bs-toggle="tab" data-bs-target="#methods" href="#methods" role="tab">Methods</a>
      </li>
      <li class="nav-item" role="presentation"><a class="nav-link" id= "patient_characteristics_tab" role="tab" data-bs-toggle="tab" href="#patient_characteristics">Patient Characteristics</a>
      </li>
      <li class="nav-item" role="presentation"><a class="nav-link" id= "primary_efficacy_endpoint_tab" role="tab" data-bs-toggle="tab" href="#primary_efficacy_endpoint">Primary Efficacy Endpoint</a>
      </li>
      <li class="nav-item" role="presentation"><a class="nav-link" id= "secondary_efficacy_endpoints_tab" role="tab" data-bs-toggle="tab" href="#secondary_efficacy_endpoints">Secondary Efficacy Endpoints</a>
      </li>
      <li class="nav-item" role="presentation"><a class="nav-link" id= "safety_tab" role="tab" data-bs-toggle="tab" href="#safety">Safety</a>
      </li>
      <li class="nav-item" role="presentation"><a class="nav-link" id = "reference_tab" role="tab" data-bs-toggle="tab" href="#reference">Reference</a>
      </li>
    </ul>
  </div>

  <div class="tab-content">
    <div id="summary" class="tab-pane show active" role="tabpanel">
      <div class="container-fluid">
        <h1>
          Özet<sup>1</sup>
        </h1>
        <ul class="bullet">
          <li>
            VICTORIA, azalmış ejeksiyon fraksiyonu (EF) ve yakın zamanda dekompanse KY ile kronik kalp yetmezliği (KY) olan hastalarda verisiguatın etkililiğini ve güvenliliğini değerlendiren, faz 3, randomize, çift kör, plasebo kontrollü bir çalışmadır.
          </li>
          <li>
            Medyan 10.8 ay boyunca, kardiyovasküler ölüm (CVD) veya kalp yetmezliği nedeniyle hastaneye yatış (HFH) birincil bileşik sonlanım noktası, verisiguat grubunda 897/2526 (%35.5) ve plasebo grubunda 972/2524 (%38.5) olarak gerçekleşmiştir (hazard ratio 0.90; %95 güven aralığı [CI] 0.82 - 0.98; P = 0.02).
          </li>
          <li>
            <a id="link" onclick="link6()">Yan etki (AE’ler) oranları</a>, wverisiguat ve plasebo arasında benzer bulunmuştur.
          </li>
          <li>
            Klinik açıdan ilgili önceden belirlenmiş advers olaylar için sırasıyla verisiguat ve plasebo ile semptomatik hipotansiyon (sırasıyla %9.1 ve %7.9) ve senkop (sırasıyla %4 ve %3.5) oranlarında küçük farklılıklar gözlenmiştir.
          </li>
        </ul>
      </div><br><br>
    </div>

    <div id="methods" class="tab-pane"  role="tabpanel">
      <div class="container-fluid">
        <h1>
          Methods<sup>1</sup>
        </h1>
        <ul class="bullet">        
          <li>
            The patient population included subjects &ge;18 years of age with chronic HF (NYHA functional classes II to IV) and reduced EF of &lt;45% within 12 months before randomization, elevated natriuretic peptide levels within 30 days prior to randomization, and a previous HF decompensation  (defined as HFH within previous 6 months or use of intravenous diuretics for HF without hospitalization within previous 3 months).
          </li>
        </ul>
      </div><br><br>
    </div> 
          
    <div id="patient_characteristics" class="tab-pane" role="tabpanel">
      <div class="container-fluid">
        <h1>Patient Characteristics<sup>1</sup></h1>
        <ul class="bullet">
          <li>
            5050 patients were enrolled in VICTORIA and followed for a median of 10.8 months.
          </li>
          <li>
            Use of concomitant guidelines-based medical therapy was well balanced: 60% of patients received triple therapy (a beta blocker and a mineralocorticoid antagonist combined with either an ACEI, an ARB, or an ARNI), and 15% received ARNI therapy.
          </li>
          <li>
            The baseline characteristics were well-matched between the two groups.
          </li>
        </ul>
      </div>
    </div>

    <div id="primary_efficacy_endpoint" class="tab-pane" role="tabpanel">
      <div class="container-fluid">
        <h1>
          Primary Efficacy Endpoint<sup>1</sup>
        </h1>
        <ul class="bullet">
          <li>
            The annual event rate of the primary composite endpoint of CVD or HFH in the vericiguat treatment group was 33.6% vs 37.8% in the placebo group, resulting in an ARR of 4.2 events per 100 patient-years.
          </li>
        </ul>

        <div class="container-collapse">
          <a class="btn btn-collapse" data-bs-toggle="collapse" aria-expanded="false" aria-controls="collapse-2" href="#collapse-2" role="button">Click to Expand/Collapse <br> Primary Outcome
          </a>
        </div>

          <div id="collapse-2" class="collapse">
            <h2>
              Primary Outcome
            </h2>
            <div class="figure zoom">
              <img src="assets/img/primary_outcome.PNG" 
              class="img-fluid">
          </div>
        </div>
        <br>
        <ul class="bullet">
          <li>
            The effect of vericiguat relative to placebo on the primary composite endpoint was generally consistent across the prespecified subgroups - although this was not the case in subgroups defined by NT-proBNP level. 
          </li>
        </ul>
        <div>
          <div class="container-collapse">
            <a class="btn btn-collapse" data-bs-toggle="collapse" aria-expanded="false" aria-controls="collapse-3" href="#collapse-3" role="button">
              Click to Expand/Collapse <br> NT-proBNP Subgroup Effects
            </a>
          </div>
            <div id="collapse-3" class="collapse">
              <div class="figure">
                <img src="assets/img/NTprobnp.PNG" 
                    class="img-fluid">
              </div>
            </div>
        </div>
      </div>
    </div>
      
    <div id="secondary_efficacy_endpoints" class="tab-pane" role="tabpanel">
      <div class="container-fluid">
        <h1>
          Secondary Efficacy Endpoints<sup>1</sup>
        </h1>
        <ul class="bullet">
          <li>
            The secondary outcomes were the individual components of the primary outcome, first and subsequent HFH, a composite of death from any cause or first HFH, and death from any cause.
          </li>
        </ul>
        <h2>
          Secondary Outcomes
        </h2>
          <div class="figure">
            <img src="assets/img/secondary_outcomes.PNG" 
              class="img-fluid">
          </div>
          </div>
        </div>
    
    <div id="safety" class="tab-pane" role="tabpanel">
      <div class="container-fluid">
        <h1>
          Safety<sup>1</sup>
        </h1>
        <ul class="bullet">
          <li>
            Overall frequency of AEs was similar between groups.
            <ul>
              <li>
                AEs (serious and nonserious) occurred in 80.5% of vericiguat patients vs 81.0% for placebo.
              </li>
              <ul>
                <li>
                  Serious AEs occurred in 32.8% of vericiguat patients vs 34.8% for placebo.
                </li>
              </ul>
            </ul>
          </li>
          <li>
            For the prespecified adverse events of clinical interest - small differences in the rates of symptomatic hypotension (9.1% vs 7.9%, respectively; P=0.12) and syncope (4% vs 3.5%, respectively; P=0.30) were observed with vericiguat and placebo.
          </li>
        </ul>
      </div>
    </div>

    <div id="reference" class="tab-pane" role="tabpanel">
      <div class="container-fluid">
        <h1>
          Reference
        </h1>
        <ol style="margin-left: 30px; margin-right: 30px; margin-top: -20px; padding-right: 30px; padding-left: 30px; padding-bottom: 10px; padding-top: 10px; font-size: 20px;background-color: #f7f7f7;">
          <li>
            Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <em>N Engl J Med</em>. 2020;382(20):1883-1893.
            <br><a href="https://pubmed.ncbi.nlm.nih.gov/32222134/" target="_blank">PMID: 32222134</a>
          </li>
        </ol>
      </div>
    </div><br><br>
  </div>

  <footer class="fixed-bottom">
    <div class="container-fluid">
      <button type="button" class="btn btn-abbrev" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" onclick="changeIcon(this)" title="Abbreviations" data-bs-content="
        <strong>ACEI</strong> angiotensin-converting enzyme inhibitor<br>
        <strong>AE</strong> adverse event<br>
        <strong>ARB</strong> angiotensin II receptor blocker<br>
        <strong>ARNI</strong> angiotension receptor-neprilysin inhibitor<br>
        <strong>ARR</strong> absolute event rate-reduction<br>
        <strong>CV</strong> cardiovascular<br>
        <strong>CVD</strong> cardiovascular death<br>
        <strong>EF</strong> ejection fraction<br>
        <strong>HF</strong> heart failure<br>
        <strong>HFH</strong> heart failure hospitalization<br>
        <strong>HR</strong> hazard ratio<br>
        <strong>mo</strong> month<br>
        <strong>no.</strong> number<br>
        <strong>NT-proBNP</strong> N-terminal prohormone of brain natriuretic peptide<br>
        <strong>NYHA</strong> New York Heart Association<br>
        <strong>yr</strong> year<br>">
      <i id ="fa" class="fas fa-list"></i>
      </button>

  <button type="button" class="btn btn-ref" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" title="Reference" onclick="changeIcon(this)" data-bs-content="
    <ol>
      <li>
        Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <em>N Engl J Med</em>. 2020;382(20):1883-1893.
        <br><a href='https://pubmed.ncbi.nlm.nih.gov/32222134/' target='_blank'>PMID: 32222134</a>
      </li>
   </ol>">
   <i id="fa" class="fas fa-scroll"></i>
  </button>
  </div>
  <a href="#" id="scroll" style="display: none;"><span></span></a>
  </footer>   
   
  <script>  
    var popoverTriggerList = [].slice.call(document.querySelectorAll('[data-bs-toggle="popover"]'))
    var popoverList = popoverTriggerList.map(function (popoverTriggerEl) 
    {
      return new bootstrap.Popover(popoverTriggerEl)
    });
  </script>   
</body>
</html>